Table 3 Cox regression analysis for progression-free survival grouped by low or high baseline levels using the median as a cutoff value
From: Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer
Progression-free survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|
N | n | Age-adjusted HR | 95% CI | p value | Multivariable adjusted HRa | 95% CI | p value | ||
NRP-1 | ng/ml | ||||||||
Low | ≤ 236.3 | 26 | 10 | 1 | 1 | ||||
High | > 236.3 | 27 | 21 | 1.98 | 0.92–4.25 | 0.07 | 2.90 | 1.02–8.28 | 0.04 |
PlGF | pg/ml | ||||||||
Low | ≤ 24.7 | 27 | 15 | 1 | 1 | ||||
High | > 24.7 | 26 | 16 | 1.54 | 0.71–3.32 | 0.26 | 1.98 | 0.84–4.63 | 0.11 |
VEGF-A | pg/ml | ||||||||
Low | ≤ 101.9 | 26 | 12 | 1 | 1 | ||||
High | > 101.9 | 27 | 19 | 1.47 | 0.70–3.10 | 0.30 | 1.50 | 0.69–3.25 | 0.30 |
VEGF-C | ng/ml | ||||||||
Low | ≤ 1.6 | 28 | 16 | 1 | 1 | ||||
High | > 1.6 | 25 | 15 | 1.13 | 0.55–2.32 | 0.73 | 1.26 | 0.58–2.73 | 0.54 |
VEGF-D | pg/ml | ||||||||
Low | ≤ 260.5 | 26 | 13 | 1 | 1 | ||||
High | > 260.5 | 27 | 18 | 1.29 | 0.61–2.70 | 0.50 | 0.72 | 0.30–1.75 | 0.47 |
VEGFR-1 | pg/ml | ||||||||
Low | ≤ 125.5 | 27 | 14 | 1 | 1 | ||||
High | > 125.5 | 26 | 17 | 1.66 | 0.81–3.39 | 0.16 | 1.56 | 0.67–3.61 | 0.29 |
VEGFR-2 | ng/ml | ||||||||
Low | ≤ 11.0 | 27 | 19 | 1 | 1 | ||||
High | > 11.0 | 26 | 12 | 0.44 | 0.21–0.93 | 0.03 | 0.43 | 0.19–0.98 | 0.04 |
VEGFR-3 | ng/ml | ||||||||
Low | ≤ 43.5 | 27 | 18 | 1 | 1 | ||||
High | > 43.5 | 26 | 13 | 0.88 | 0.42–1.82 | 0.74 | 0.58 | 0.23–1.41 | 0.23 |